Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Anemia, Refractory, with Excess of Blasts 2Lymphoma, Mantle-Cell 1Hemoglobinuria, Paroxysmal 1Glioblastoma 1Anemia, Aplastic 1

Interventions

fludarabine phosphate 14Cyclophosphamide 14Whole-Body Irradiation 12Tacrolimus 10Melphalan 10Mycophenolic Acid 9Busulfan 8fludarabine 7Peripheral Blood Stem Cell Transplantation 7Methotrexate 4Antilymphocyte Serum 4Alemtuzumab 4thymoglobulin 3Thiotepa 2Stem Cell Transplantation 2Sirolimus 2Etoposide 2Cyclosporine 2AP 1903 reagent 2visilizumab 1sargramostim 1methanesulfonic acid 1merphos 1Transplantation 1Teriparatide 1Rituximab 1Radiotherapy 1Radiation 1Parathyroid Hormone 1Methylprednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Anemia, Aplastic × Basiliximab × Clear all
NCT00975975 2016-02-26

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

Indiana University

Phase 2 Completed
17 enrolled 9 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Anemia, Refractory, with Excess of Blasts, Hemoglobinuria, Paroxysmal, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡